Unknown

Dataset Information

0

Re-irradiation of recurrent glioblastoma using helical TomoTherapy with simultaneous integrated boost: preliminary considerations of treatment efficacy.


ABSTRACT: Although there is still no standard treatment for recurrent glioblastoma multiforme (rGBM), re-irradiation could be a therapeutic option. We retrospectively evaluated the efficacy and safety of re-irradiation using helical TomoTherapy (HT) with a simultaneous integrated boost (SIB) technique in patients with rGBM. 24 patients with rGBM underwent HT-SIB. A total dose of 20 Gy was prescribed to the Flair (fluid-attenuated inversion recovery) planning tumor volume (PTV) and 25 Gy to the PTV-boost (T1 MRI contrast enhanced area) in 5 daily fractions to the isodose of 67% (maximum dose within the PTV-boost was 37.5 Gy). Toxicity was evaluated by converting the 3D-dose distribution to the equivalent dose in 2 Gy fractions on a voxel-by-voxel basis. Median follow-up after re-irradiation was 27.8 months (range 1.6-88.5 months). Median progression-free survival (PFS) was 4 months (95% CI 2.0-7.9 months), while 6-month PFS was 41.7% (95% CI 22.2-60.1 months). Median overall survival following re-irradiation was 10.7 months (95% CI 7.4-16.1 months). There were no cases of re-operation due to early or late toxicity. Our preliminary results suggest that helical TomoTherapy with the proposed SIB technique is a safe and feasible treatment option for patients with rGBM, including those large disease volumes, reducing toxicity.

SUBMITTER: Arpa D 

PROVIDER: S-EPMC7653937 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Re-irradiation of recurrent glioblastoma using helical TomoTherapy with simultaneous integrated boost: preliminary considerations of treatment efficacy.

Arpa Donatella D   Parisi Elisabetta E   Ghigi Giulia G   Savini Alessandro A   Colangione Sarah Pia SP   Tontini Luca L   Pieri Martina M   Foca Flavia F   Polico Rolando R   Tesei Anna A   Sarnelli Anna A   Romeo Antonino A  

Scientific reports 20201109 1


Although there is still no standard treatment for recurrent glioblastoma multiforme (rGBM), re-irradiation could be a therapeutic option. We retrospectively evaluated the efficacy and safety of re-irradiation using helical TomoTherapy (HT) with a simultaneous integrated boost (SIB) technique in patients with rGBM. 24 patients with rGBM underwent HT-SIB. A total dose of 20 Gy was prescribed to the Flair (fluid-attenuated inversion recovery) planning tumor volume (PTV) and 25 Gy to the PTV-boost (  ...[more]

Similar Datasets

| S-EPMC8881492 | biostudies-literature
| S-EPMC3341183 | biostudies-literature
| S-EPMC7931514 | biostudies-literature
| S-EPMC5551002 | biostudies-other
| S-EPMC4998049 | biostudies-literature
| S-EPMC5875514 | biostudies-literature
| S-EPMC10256803 | biostudies-literature
| S-EPMC10485381 | biostudies-literature
| S-EPMC7190867 | biostudies-literature
| S-EPMC2799427 | biostudies-literature